Principal Financial Group Inc Reata Pharmaceuticals Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$79.22 - $105.37 $74,546 - $99,153	-941 Reduced 11.77%	7,051 $718,000
Q1 2023 May 09, 2023	SELL	$30.85 - $93.17 $6,385 - $19,286	-207 Reduced 2.52%	7,992 $726,000
Q4 2022 Feb 09, 2023	BUY	$22.15 - $42.11 $181,607 - $345,259	8,199 New	8,199 $311,000
Q2 2022 Aug 10, 2022	BUY	$20.71 - $36.5 $152,653 - $269,041	7,371 New	7,371 $224,000
Q4 2021 Feb 09, 2022	SELL	$25.61 - $110.96 $297,639 - $1.29 Million	-11,622 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$100.0 - $143.02 $22,100 - $31,607	221 Added 1.94%	11,622 $1.17 Million
Q2 2021 Aug 10, 2021	BUY	$78.27 - $151.29 $186,752 - $360,977	2,386 Added 26.47%	11,401 $1.61 Million
Q1 2021 May 10, 2021	BUY	$94.25 - $132.81 $28,840 - $40,639	306 Added 3.51%	9,015 $899,000
Q4 2020 Feb 08, 2021	SELL	$102.03 - $184.62 $510 - $923	-5 Reduced 0.06%	8,709 $1.08 Million
Q3 2020 Nov 06, 2020	SELL	$93.53 - $163.34 $488,320 - $852,798	-5,221 Reduced 37.47%	8,714 $848,000
Q2 2020 Aug 05, 2020	BUY	$126.3 - $176.56 $424,368 - $593,241	3,360 Added 31.77%	13,935 $2.17 Million
Q1 2020 May 12, 2020	BUY	$124.16 - $247.74 $207,968 - $414,964	1,675 Added 18.82%	10,575 $1.53 Million
Q4 2019 Feb 05, 2020	BUY	$74.57 - $217.92 $35,495 - $103,729	476 Added 5.65%	8,900 $1.82 Million
Q3 2019 Nov 13, 2019	BUY	$71.26 - $95.75 $11,971 - $16,086	168 Added 2.03%	8,424 $676,000
Q2 2019 Aug 12, 2019	BUY	$77.72 - $94.35 $72,823 - $88,405	937 Added 12.8%	8,256 $779,000
Q1 2019 May 10, 2019	BUY	$51.9 - $101.79 $379,856 - $745,001	7,319 New	7,319 $626,000
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $149,644 - $234,594	-3,069 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$35.64 - $92.06 $109,379 - $282,532	3,069 New	3,069 $251,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account